1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
July 2021 in “The Egyptian Journal of Hospital Medicine” Intralesional Triamcinolone acetonide injections are safe and effective for treating alopecia areata.
March 2026 in “Expert Opinion on Pharmacotherapy” JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
January 2025 in “SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital” PRP injections are safe and effective for alopecia areata, but steroids are still the preferred treatment.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
1 citations
,
April 2012 in “Informa Healthcare eBooks” Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
7 citations
,
June 2007 in “AIDS” A man's hair loss was linked to his HIV medication, which improved after changing drugs.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
1 citations
,
August 2025 in “Australasian Journal of Dermatology” Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.